

## **Metalloprotease Type III effectors that specifically cleave JNK and NF- $\kappa$ B**

Kobi Baruch<sup>1</sup>, Lihi Gur-Arie<sup>1</sup>, Chen Nadler<sup>1</sup>, Simi Koby<sup>1</sup>, Gal Yerushalmi<sup>1</sup>, Yinon Ben-Neriah<sup>2</sup>, Orli Yogev<sup>3</sup>, Eitan Shaulian<sup>3</sup>, Chen Guttman<sup>4</sup>, Raz Zarivach<sup>4</sup> and Ilan Rosenshine<sup>1</sup>

Departments of Microbiology and Molecular Genetics<sup>1</sup>, Immunology and Cancer Research<sup>2</sup>, and Biochemistry and Molecular Biology<sup>3</sup>, IMRIC, The Hebrew University of Jerusalem, Faculty of Medicine, POB 12272, Jerusalem 91120, Israel. Department of Life Sciences and the National Institute of Biotechnology<sup>4</sup>, Ben-Gurion University of the Negev, POB 12272 Beer-Sheva 84105, Israel

**Table S1 – The strains used in this study**

Name	Description	Reference or source
E2348/69	EPEC wild-type	J. Kaper
SN1961	E2348/69 $\Delta escV::kan$	(Nadler et al., 2006)
EM3321	E2348/69 $\Delta PP2::kan$	(Nadler et al., 2010)
EM3331	E2348/69 $\Delta PP6::kan$	(Nadler et al., 2010)
EM3345	E2348/69 $\Delta IE5::kan$	(Nadler et al., 2010)
EM3347	E2348/69 $\Delta IE6::kan$	(Nadler et al., 2010)
EM3325	E2348/69 $\Delta PP4::kan$	(Nadler et al., 2010)
SK4240	E2348/69 $\Delta IE6::cm \Delta PP4::kan$	This study
KB4298	E2348/69 $\Delta nleD::kan$	This study
KB4296	E2348/69 $\Delta nleC::kan$	This study
ICC168	<i>Citrobacter rodentium</i> (CR) wild-type	(Wiles et al., 2004)
BL21(DE3)	F-, ompT, hsdS $\beta$ (r $\beta$ -m $\beta$ -), dcm, gal, (DE3) tonA	Novagen
EM3326	E2348/69 $\Delta IE2::cm$	(Nadler et al., 2010)
KB4309	E2348/69 $\Delta IE2::cm \Delta nleBE_{IE6}::tet$	(Nadler et al., 2010)
KB4325	E2348/69 $\Delta IE2::cm \Delta nleBE_{IE6}::tet \Delta nleC::kan$	This study
KB4329	E2348/69 $\Delta IE2::cm \Delta nleBE_{IE6}::tet \Delta nleCD::kan$	This study

**Table S2 – The plasmids used in this study**

Name	Description	Reference or source
pSA10	pKK177-3 derivative containing <i>lacI</i> <sup>r</sup>	(Schlosser-Silverman et al., 2000)
pKB4345	pSA10 encoding <i>nleD</i> from EPEC	This study
pLG4457	pSA10 encoding <i>nleD</i> -E143A from EPEC	This study
pKB4505	pSA10 encoding <i>nleD1</i> from CR	This study
pKB4506	pSA10 encoding <i>nleD2</i> from CR	This study
pSC4141	A plasmid expressing <i>mCherry</i> deleted of its stop codon and with <i>Scal</i> site added	(Nadler et al., 2010)
pLG4419	pSC4141 encoding <i>nleD</i> from EPEC	This study
pLG4477	pSC4141 encoding <i>nleD</i> -E143A from EPEC	This study
pCX341	Vector for formation of fusions with the <i>blaM</i> reporter	(Mills et al., 2008)
pME3654	pCX341 encoding <i>nleD</i> - <i>blaM</i>	This study
pKB4344	pSA10 encoding <i>nleC</i>	This study
pKB4403	pSA10 encoding <i>nleC</i> -E184A	This study
pSC4104	pSA10 containing <i>nleBE</i> IE6-6His with its promoter region	(Nadler et al., 2010)

pHG3656	pCX341 encoding <i>nleG-blaM</i>	This study
pET28a	Expression vector	Novagen
pRL-TK	Constitutively expressing renilla luciferase vector	Promega
pNFkB-luc	A plasmid expressing <i>luc</i> under NF- $\kappa$ B-dependent promoter	(Yaron et al., 1998)
pKB4745	pEGFP-N1 (clontech) with <i>nleD</i>	This study
pKB4746	pET14b (Novagen) with p65 1-210	This study
pHA-JNK	Vector for expression of HA-tagged JNK	(Kallunki et al., 1994)
pME3660	pCX341 encoding <i>nleC-blaM</i>	This study
pKB4407	pCX341 encoding <i>nleC-E184A -blaM</i>	This study
pLG4484	pCX341 encoding <i>nleD-E143A -blaM</i>	This study

**Table S3 – The primers used in this study**

Name	Sequence	Usage
<b>Primers used for cloning</b>		
<i>nleD</i> _into_pSA10_F (1075)	AGAATTCATGCGCCCTACGTCCCTCAAC	pKB4345, pKB4745 (EcoRI)
<i>nleD</i> _into_pSA10_R (1076)	ACCGTCGACCAGCTAAAGCAATGGATGCAG	pKB4345 (Sall)
<i>nleD</i> 1 Citro into pSA10 F (1173)	AGAATTCCTTAATGCGCCCTACATCCC	pKB4505 (EcoRI)
<i>nleD</i> 1 Citro into pSA10 R (1174)	ACCGTCGACCAACGTAGCTAAAGTAACGG	pKB4505 and pKB4506 (Sall)
<i>nleD</i> 2 Citro into pSA10 R (1175)	AGAATTCATGGTATTTTCAGCCAAACC	pKB4506 (EcoRI)
<i>nleD</i> into pSC4141 F (1105)	ATCCTGAGTACTCGATGCGCCCTACGTCCCTC	pLG4419 and pLG4477 (ScaI)
<i>nleD</i> into pSC4141 R (1106)	GCATGCGGCCCGCTAAAGCAATGGATGCAGTC	pLG4419 and pLG4477 (NotI)
<i>nleD</i> Fw (831)	GGTTGGGTACCATGCGCCCTACGTCCCTCAA	pHG3654 (KpnI)
<i>nleD</i> Rv (832)	GCGAATTCCCAAGCAATGGATGCAGTCTTAC	pHG3654 (EcoRI)
<i>nleC</i> _into_pSA10_F (1073)	AGAATTCATGAAAATTCCTCATTACAG	pKB4344 (EcoRI)
<i>nleC</i> _into_pSA10_R (1074)	ACCGTCGACTCATCGCTGATTGTGTTTGTC	pKB4344 (ScaI)
<i>nleG</i> Fw (840)	GGTTGGGTACCATGCCATCATTAGTTTCAGGTA	pHG3656 (KpnI)
<i>nleG</i> Rv (841)	GCGAATTCCCCTTATCCTTTATGACAAAAGTTTC	pHG3656 (EcoRI)
p65 1-210 F (1235)	AATGCACATATGGACGAACTGTTCCCC	pKB4746 (NdeI)
p65 1-210 R (1236)	ACTCGAGTTAATCCCCACCGAGGCAGC	pKB4746 (XhoI)
<i>nleD</i> into EGFP N1 R (1226)	CGGTGACAGCAATGGATGCAGTCTTAC	pKB4745 (Sall)
<b>Primers for deletions</b>		
<i>nleB</i> _tet_F (946)	CCGTCTAAATGACGGGGCGATATTAACATGATTA GAACAAGAGGAATTTTCAAGAGGGTCATTATATT TCG	KB4309
<i>nleE</i> _tet_R (949)	TAATGAAATAGAATTAATTTTAGCCCCCTACAC AAGTGGCTGAGCTTCTACTCGACATCTTGGTTAC CG	KB4309
<i>nleC</i> KO F (1060)	TTGTTGTAATAAATGATTTGCAGGGTATTAGATA TAAACATGAAAATTCCTGTTAGGCTGGAGCTGC TTC	KB4325
<i>nleC</i> KO R (1061)	TAAAATGTATGAATAGTAACCTTATGTCACCTGCA	KB4325

	AAGACGAATCATCGCTGCATATGAATATCCTCCTTAG	
8M NO (K/O) F (628)	TTAATTATCAGTAAATTAATGTAAGTAGGTCATT ATTAGTCAAAATAAAAAGTGTAGGCTGGAGCTGCTTC	SK4240
nleD KO F (1062)	TAAACAGGCTGCTAATAAGTAGCATTCTCAGGAG TCCTGATGCGCCCTACGGTGTAGGCTGGAGCTGCTTC	KB4298
8M NO (K/O) R (629)	TGTGTGCCTCCGTTTGTCCCAATATATATATTC AGCACAAGAAACACAGCATATGAATATCCTCCTTAG	SK4240, KB4298
<b>Primers used for Mutagenesis</b>		
<i>nleD</i> mut1 F (1151)	GACTATTGTTTTTCATGCGTTGCTCCATGTTTTTC C	<i>nleD</i> E143A
<i>nleD</i> mut1 R (1152)	GGAAAACATGGAGCAACGCATGAAAAACAATAGT C	<i>nleD</i> E143A
<i>nleC</i> mut2 F (1095)	CAGGAAGGACTGATTACGCGATTATTCATCATG TTAC	<i>nleC</i> E184A
<i>nleC</i> mut2 R (1096)	GTAACATGATGAATAATCGCGTGAATCAGTCCTT CCTG	<i>nleC</i> E184A


List of antibodies used in this study and working conditions:

1. Anti-p65-C-terminus domain (SC-372, Santa Cruz, 1:1000 in TBS)
2. Anti-p65-N-terminus domain (SC-109, Santa Cruz, 1:1000 in TBS)
3. Anti-JNK (554285, BD Pharmingen, 1:1000 in TBS)
4. Anti-HA,
5. Anti-6His (27471001, GE Healthcare, 1:3000 in TBS)
6. Anti-ERK (m5670, Sigma, 1:2500 in TBS)
7. Anti-c-Jun (H79, SCBT)
8. Anti-phospho-c-Jun (Cell Signaling)

Protein expression and purification

Plasmids expressing His-tagged NleC, NleC-E184A, NleD and p65<sub>1-210</sub> were transformed into *E. Coli* BL21 (DE3) and bacteria were grown to mid-exponential phase at which their expression was induced by incubation with either 1 mM IPTG at

20° C for 18 hours (NleC and NleC-E182A) or by the auto induction protocol at the same physical settings (Studier, 2005). Cells were collected by centrifugation at 6000 rpm for 7 min at 4° C after which the pellet was resuspended with binding buffer (20 mM Imidazole, 300 mM NaCl, 20 mM TRIS, pH 8, 0.02% Triton X-100). 10 mM, 6 mM and 3mM  $\beta$ -mercaptoethanol were added to the binding buffer of p65<sub>1-210</sub>, NleC and NleC-E184A, respectively. Suspensions were lysed using French Press (Thermo Scientific) and centrifuged at 45,000 rpm for 45 min at 4° C. Protein batch binding was conducted by applying the supernatant to a Ni-NTA beads (Novagen), followed by 3 washing steps on a dripping column: step 1 buffer (25 ml of 300 mM NaCl, 20 mM Imidazole, 20 mM TRIS, pH 8), step 2 buffer (50 ml of 600 mM NaCl, 30 mM Imidazole, 20 mM TRIS, pH 8) and step 3 buffer (25 ml of 300 mM NaCl, 40 mM Imidazole, 20 mM TRIS, pH 8). Elution was performed in the presence of elution buffer (50 mM NaCl, 300 mM Imidazole, 20 mM TRIS, pH 8) after which eluted samples were equilibrated overnight against dialysis buffer (50 mM NaCl, 20 mM TRIS, pH 8) at 4° C with 5000 MW cutoff SnakeSkin<sup>®</sup> (Thermo Scientific). Equilibrated samples were purified with Mono-Q anion exchange column (GE healthcare) utilizing linear gradient with elution buffer (2M NaCl, 20 mM TRIS, pH 8). Selected fractions were further purified by size exclusion column (GE healthcare) equilibrated against 50 mM NaCl, 20 mM TRIS, pH 8. The collected fractions were pooled and concentrated to 44 mg·ml<sup>-1</sup>, 34.5 mg·ml<sup>-1</sup>, 16 mg·ml<sup>-1</sup> and 8 mg·ml<sup>-1</sup> (NleC, NleC-Mut, NleD and p65<sub>1-210</sub>, respectively).



**Fig S1. JNK degradation upon infection with different EPEC mutants**

**A. EPEC deleted of the PP4 chromosomal region is deficient in inducing JNK degradation.**

HeLa cells were infected for 3 h with different EPEC strains containing deletion of large chromosomal regions (the deleted regions are indicated above the lanes). Proteins were then extracted and subjected to Western blot analysis with anti-JNK antibody. The locations of the intact and fragmented JNK proteins are indicated. Mutant with inactivated TTSS ( $\Delta escV$ ) was used as negative control.

**B. Complete JNK degradation by EPEC.** HeLa cells were infected with EPEC for different periods with wild type EPEC (WT) or *nleD* mutant ( $\Delta nleD$ ), as indicated above the lanes. Proteins were then extracted and subjected to Western blot analysis with anti-JNK antibody. The locations of the intact and fragmented JNK proteins are indicated.

```

EPEC      MRPTSLNVLVHQSG---STSSMSDIEDIEISLVKASSVQWIKNNPQLRFQGTDHNIYQQIEA 57
EHEC      MRPTSLNVLVHQSG---SRSSMSDIEDIEISLVKASSVQWIKNNPQLRFQGTDHNIYQQIEA 57
CR        MRPTSLNLTLPSPPLPSSSNSISATDIQSLVKMSGVRWVKNNQQLCFHGTDLKIYQHLEA 60
SE        -----MRWIKNNQQLSFHGTDHKIYQQLEA 25
HD        MR-RALKLNLTPLS--FSSSNSDIEDIQLSLVKKSSVNWIKNNHQLSFDGTNKNIYQRLEK 57
          :.*:*** ** *.** :***:**

EPEC      ALDKIGSTETGRVLLNAIESISRLKSETVV IHLNSSRLGVMARHDIDAENHRGTGSDFHC 117
EHEC      ALDKIGSTETGRVLLNAIESISRLKSETVV IHLNSSRLGVMARHDIDAENHRGTGSDFHC 117
CR        ALDKIESTDTGRTLLNCIELTSRLKSEKLA IHLDSAELGVIAHCNADAENSRGTGSDFHC 120
SE        ALDKIESTDTGRILLKCIELTSQLKSEKLA IHLNCAELGVVAHCNTDAENARGTGSDFHC 85
HD        ALDKIESTETGKELLNCIESVSRKSEKLI IRLDSTELGVTAHCAENAENFRGTGSYLHC 117
          ***** **:**: **:.* *:*:**: **:.:.* ** * :** ***** :**

EPEC      NLNAVEYP-CGEGISVVDVFHATIVFHELLHVFHNLNGERLKVESSRPESQKYSPLLEEAA 176
EHEC      NLNAVEYP-CGEGISVVDVFHATIVFHELLHVFHNLNGERLKVESSRAESQKYSPLLEEAA 176
CR        NLNAVEYP-CGQGISLVDFHACIVFHELLHVFHNLNGERLKVESSQPELQTHSPLLEEAA 179
SE        NLNAVAYP-CGQGISLVDFHACIVFHELLHVLHNLNGERLKVESSQPESQTHYPFLLEEAA 144
HD        NLNSVQEEISIGKGIQTELDACIVFHELLHVFHNLNGERLKVAVFQPEVETYSPLLEEAA 177
          ***:*      **:.:.* *******:***** ** :.* :.: *******


EPEC      RTVGLGAFSEEVLSENKFREEIGMPRRTSYPHDSALIHDDNTVSLGFQQVRLHPLL 232
EHEC      RTVGLGAFSEEVLSENKFHEEIGMPRRTSYPXDSALIHDDNTVSLGFQQVRLHPLL 232
CR        RTVGLGAFSEEVLSENKFREEIGMPRRTFYPHDSL IHDNTVTQGFQRKKLHPLL 235
SE        RTVGLGSFSEEVLSENKFREEIGVPRRTFYPRDPYL IHDNTVTQGLQRKKLHPLL 200
HD        RTVGLGSFSEEVFSENKFREEIGIPRRVSYAHESLIHDDNTFTMFFENKQSHPLL 233
          *****:*****:*****:*****:***. *. :. *****.: :.: : ****

```

### Fig. S2. Multiple alignment of NleD homologs


The NleD protein sequences of EPEC (*Escherichia coli* O127:H6 str. E2348/69), EHEC (*Escherichia coli* O157:H7 EDL933), CR (*Citrobacter rodentium* ICC168 – has two copies of the *nleD* gene, encoding for an identical protein), SE (*Salmonella enterica* subsp. arizonae serovar 62:z4,z23:-- ) and HD (Candidatus *Hamiltonella defensa* 5AT) were aligned using ClustalW2. The HExxH Zn-metalloprotease motif is highlighted.






**Fig. S3. NleD is required for EPEC-induced cleavage of JNK, *in vivo*, upon infection of Caco2 cells**

Caco2 cells were infected for 3 h with different EPEC strains as indicated above the lanes or remain non infected (NI). Proteins were then extracted and subjected to Western blot analysis with anti-JNK antibody. The locations of the intact and fragmented JNK proteins are indicated. Mutant with inactivated TTSS ( $\Delta escV$ ) was used as negative control. In addition *nleC* mutant and a complemented mutant were used to show that NleC has no effect on JNK. The expression of native or plasmid expressed NleC and NleD is indicated below the blot. Expression is indicated by (+) and lack of expression by (-).




**Fig. S4. Co-precipitation of the N- and C- terminal fragments of cleaved 6His-JNK2**

Purified 6His-JNK2 was treated with Purified NleD to allow cleavage and the reaction products were further purified by gel filtration. Next, the proteins in a fraction containing the cleaved JNK2 were pulled down by Agaros-Ni beads, washed and eluted. The eluted proteins were analyzed by SDS-PAGE and Western blot using anti-6His (recognizing the N-terminus fragment of 6His-JNK2) and anti-JNK (recognizing the C-terminus fragment of JNK2). The locations of the JNK fragments and intact JNK2 are indicated. The remains of un-cleaved JNK2, which were seen with the anti-JNK, were not detected with the anti-6His antibody since the latter is less sensitive.



**Fig. S5. NleD induces cleavage of HA-JNK1, *in vivo*, at its activation loop**

HEK293 cells were transfected with a plasmids expressing JNK1, N-terminally tagged with the HA epitope. After 25 h, the cells were infected with wild type EPEC, or with EPEC *nleD* mutant and after 2.5 h infection the proteins were extracted from the infected cells and HA-JNK was immunoprecipitated with anti-HA antibodies. The precipitated proteins were analyzed using Western blot with either anti-HA; recognizing the N-terminal of HA-JNK1(B), or anti-JNK; recognizing the C-terminal of HA-JNK1 (C). Analysis with the anti-HA and anti-JNK antibodies identified N-terminal fragment of ~23 kD in size, and C-terminal fragments of ~24 kD in size. The latter is shorter from the JNK2 C-terminus fragment seen in Fig. 2, since JNK1 C-terminus region is shorter than that of JNK2. These results indicate that the C-terminal portion of the clipped HA-JNK1 remained in complex, and co-precipitated, with the HA-tagged N-terminus fragment. Based on the predicted size of the C- and N- terminal fragments generated by NleD digestion we estimated that, like in the case of JNK2 (Fig 2), NleD cut JNK1 within the activation loop (A).



**Fig. S6. NleC and NleD exhibit steady state levels in the bacteria and translocation efficiency, similar to those of the corresponding mutated proteins; NleC-E184A and NleD-E143A.**

A. Proteins were extracted from bacteria containing pCX341 derivatives expressing NleC, NleD, NleC-E184A, or NleD-E143A, all C-terminally tagged with TEM. The levels of the proteins in the extracts were evaluated by Western blot using anti-TEM-1 antibody as described (Mills et al., 2008).


B. EPEC strains deleted of *nleD* or *nleC* and containing plasmids expressing TEM tagged NleC, NleD, NleC-E184A, or NleD-E143A, were used for translocation assay as described (Mills et al., 2008). The used strains are indicated within the graphs. This assay reflects the amount of translocated proteins inside the host cells and this amount is determined by both the efficiency of their translocation into the HeLa cells and their stability in the HeLa cells (Mills et al., 2008). As negative control we used EPEC containing the vector (pCX341) and expressing un-fused TEM-1.

The results in A and B show that the mutated NleC and NleD exhibit similar steady state levels and translocation efficiency to that of the wild type proteins.

MSDSKCDSQFYSVQVADSTFTVLKRYQQQLKPIGSGAQGIVCAAFDTVLGINVAVKLSRP  
 FQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPOKTLEEFQDVYLVMEMLDANLCQVIH  
 MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDC~~TLKI~~LDFGLARACTNF  
~~MM~~TPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQ  
 LGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSK  
 MLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPQIYDAQLEEREHAIEEWKELIYKEV  
 MDWEERSKNGVVKDQPSDAAVSSNATPSQSSINDISSMSTEQTLASDTDSSLDASTGPL  
 EGCR


### Fig. S7. JNK2 sequence

The sequence of JNK2 is shown. The activation loop that separates the N- and C- terminal domains of JNK2 is marked in red fonts and the TPY motif is framed. NleD cuts JNK within this motif between P and Y.



**Fig. S8. Models of JNK2**

Two views of JNK are shown. The N-terminal region is colored in red and the C-terminal in blue. The activation loop, which connects the two domains, is indicated in green and the TPY motif in yellow. NleD cuts between P184 and Y185.



**Fig. S9. NleD does not affect the transcription level of IL-8.**

RKO cells were infected with different EPEC strains as indicated. The  $\Delta escV$  (TTSS deficient strain) and  $\Delta IE2, \Delta nleBE$ , were used as positive and negative controls and the influence of further deletion of *nleC*, *nleD* or both was tested. To this end the cells were infected with the different EPEC strains for 3 h to allow injection of effectors before stimulation with  $TNF\alpha$  for additional 3 h. Then RNA was extracted from the RKO cells and Real-time PCR performed to quantify IL-8 mRNA levels. Experiments were performed in triplicates and a typical experiment out of 2 is shown. Error bars indicate standard deviation.

```

EPEC      -----MKIPSLQSNFNFSAPAGYSAPIAPNRAENAYADYVLDIGKRIPLSAADLSN 51
EHEC      -----MKIPSLQSNFNFSAPAGYSAPIAPNRAENAYADYVLDIGKRIPLSAADLSN 51
CR        -----MKIPSLQPSFNFFAPAGYSAVAPNRS DNAYADYVLDIGKRIPLSAEDLGN 51
YA        MYKIILGINMKITSLQPSFNFSAQEGYSAVAPNHS DNAYADYVLDIGKRIPFSTADLGN 60
SE        -----MKISSSTPCLNFAPQKEYSAAVVPHPSKNAYADYVLETGKRIPFSAADLSN 51
          ***.* . : ** . ***.:* : .*****: *****:* : **.*

EPEC      VYESVIRAVHDSRSRLIDQHTVDMIGNTVLDALSRSTFRDAVSYGIHNEKVHIGCIKYR 111
EHEC      VYESVIRAVHDSRSRLIDQHTVDMIGNTVLDALSRSTFRDAVSYGIHNEKVHIGCIKYR 111
CR        LYENVIRAVRDSRSKLDQHTVDMIGNTILDALSRSTFRDAVSYGIHNEKVHIGCIKYR 111
YA        LYENVIRAVHDSLSRLIDQHTADMIGNTVLDALSRSTFREAVSYGIHNEVHIGCIKYR 120
SE        LYQSVIYAVHSSRSRLIDQHTANMIGNTVLDALSRSTFRDAVIYGIHNEKVQLGCI TYR 111
          :* : .** ** : . * * :*****. :*****:*****:*** *****: : : :***.*

EPEC      NEYELNEESSVKIDDIQSLTCNELYEYDVGQEPILPICEAGENDNEEPYVSFVAPD TDS 171
EHEC      NEYELNEESSVKIDDIQSLTCNELYEYDVGQEPILPICEAGENDNEEPYVSFVAPD TDS 171
CR        NEYELNGESPVKVDDIQSLTCTELYEYDVGQEPILPICEAGENDNEEPYVSFVAPD TDS 171
YA        NEYELNGESPVEVDDIQSLTCTELYEYDVGQEPVFPICEAGEDDHEEPYVSFVAPDADS 180
SE        NEYEINEDSPVGVDSIHL LTHSELYEYEAQEPILPICEARKDEHEEAYISFSAA PD TDS 171
          ***** : * . * : * . * : ** . ***** : ***** : : : * * . * * . * * : * *

EPEC      YEMPSWQEGLIHEI IHHVTGSSDP SGDSNIELGPTEILARRVAQELGWSVPDFKGYAEPE 231
EHEC      YEMPSWQEGLIHEI IHHVTGSSDP SGDSNIELGPTEILARRVAQELGWSVPDFKGYAEPE 231
CR        YEMPSWQEGLIHEI IHHVTGASDP SGDSNIELGPTEILARRVAQELGWTVPDFIGYAE PD 231
YA        YEMPSWQEGLIHEI IHHVTGASDP SRDSNIELGPTEILARRVAQELGWP IPDFIGYADPD 240
SE        CEMPSWQEGLIHEI IHHVTGAGDP LEDGNI EPGPTEILARRIAQELGWSIPEFTGYASPD 231
          ***** : * * * . * * * * * : ***** : ***** : : * * * * . * :

EPEC      REAHLRLRNLNLRQAAMRHEENERAFFERLGTISDRYEASPDFTEYSAVSNIYG YGFIQQ 291
EHEC      REAHLRLRNLNLRQAAMRHEENERAFFERLGTISDRYEASPDFTEYSAVSNIYG YGFIQQ 291
CR        REAHLRGRNLNLRQAAMRHEDNERTFFERLGMISDRYEASPDFTEYSAVSNI EYGF IQQ 291
YA        REAHLRARNLNLRQAATR HESNEGAFFERLDMISDKYEVSPDFTEYAVVSNI EYGLIQQ 300
SE        RVAHLRTRNLNLRQTATRHEDNEEAFFERLDVISEGYEASADFT EYVMSDMVKELNKP 291
          * * * * * : * * * . * * : * * * . * * : * * . * * * . . : : : :


EPEC      HDFPGLAINDNLQDAN--QIQLYHGAPYIFTFGDVDKHNQR 330
EHEC      HDFPGLAINDNLQDAN--QIQLYHGAPYIFTFGDVDKHNQQ 330
CR        HDFPGLAIDDNLQDAN--QIQLYHGAPYIFTFGDVDKHNQR 330
YA        HDFPGLAIDDNLQDAN--QIQLYHGAPYIFTFGGADRHNQR 339
SE        HDFPGLVINDNMTMDADPDQIQLYHGQPYIFTF--VDKHNQR 330
          ***** . * : * * : * * * * * * * * * * . * : * * * :

```

**Fig. S10. Multiple alignment of NleC homologs**


The NleC protein sequences of EPEC (*Escherichia coli* O127:H6 str. E2348/69), EHEC (*Escherichia coli* O157:H7 EDL933), CR (*Citrobacter rodentium* ICC168), YA (*Yersinia aldovae*) and SE (*Salmonella enterica* subsp. *enterica* serovar Javiana) were aligned using ClustalW2. The HExxH Zn-metalloprotease motif is highlighted.





**Fig. S11. Localization of transiently expressed mCherry-NleC**

HeLa cells were transfected with plasmid expression mCherry (Vector), mCherry-NleC (NleC) or mCherry-NleC-E184A (NleC-E184A). After 16 h cells were fixed and analyzed by microscopy. The mCherry-NleC proteins exhibit distribution different from that of un-fused mCherry. mCherry was distributed in the cells with some enhancement in the nuclear region and the mCherry-NleC proteins were localized predominantly to the nucleus. The appearance of mCherry and mCherry-NleC proteins in the nuclear region exhibit very different appearance. The former appear as diffuse staining with some enhancement in the nuclear region, but without define borders. In contrast the mCherry-NleC proteins staining were clearly framed in the nucleus although some cytoplasmic staining was also evident. In addition, only the mCherry-NleC staining emphasized the location of the nucleoli as darker region in the nucleus, which was contrasted against the mCherry-NleC staining.




**Fig. S12. NleC cleave p65 *in vivo* in Caco2 cells**

Caco2 cells were infected for 3 h with different EPEC strains as indicated above the lanes, or remained non infected (NI). Cytoplasmic proteins were then extracted and subjected to Western blot analysis with anti-p65 antibody. The locations of the intact and fragmented p65 proteins are indicated. Mutant with inactivated TTSS ( $\Delta escV$ ) was used as negative control.

MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPT  
IKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEELCPDRCIHSFQNLGIQC  
VKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLP  
HPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFS  
QADVHRQVAIVFRTTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDDDRHRIEE  
KRKRTYETFKSIMKKSPFSGPTDPRPPRRIAVPSRSSASVPKPAPQPYPFTSSSLSTINY  
DEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQA  
VAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQ  
GIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSSIADM  
DFSALLSQISS

### Fig. S13. The p65 sequence

The sequence of p65 is shown. The REL domain is underlined and residues that directly contact the DNA and known to be important for DNA binding are marked in red fonts. NleC cleaves p65 between the framed C and E.


**A****B**

<b>RelB</b>	134	KQRGMPFRYECEGRSAGSILGESSTE	159
<b>p65</b>	28	KQRGMRFRYK <b>CE</b> GRSAGSIPGERSTD	53
		***** :***** ** ** :	

### Fig. S14. NleC injection is associated with cleavage of RelB


A. HeLa cells were infected for 3 h with different EPEC strains as indicated above the lanes. Proteins were then extracted and subjected to Western blot analysis with anti-RelB antibody. The locations of the intact and fragmented RelB proteins are indicated. Expression of NleC correlated with RelB cleavage (in the right lane).

B. Comparison between the p65 cleavage site and the corresponding region in RelB. NleC cleave p65 between the framed C and E. This region is highly conserved and based on the size of the fragmented RelB it is possible that NleC cleaves RelB at the same site.




**Fig. S15. NleC and NleD exhibit substrate specificity.**

Cytosolic fraction of HeLa extracts was treated for different periods of time with purified NleC or NleD or remained untreated (Control), as indicated above the lanes. Reaction was stopped by boiling in SDS loading buffer, and products were visualized by Western blot analysis using anti-p65 and anti-JNK antibodies. Intact and clipped p65 and JNK are indicated.



**Fig. S16. A model of p65-DNA interaction**

A model of p65 (green) bound to DNA (magenta) is shown (Chen et al., 1998). The clipped N-terminal region is colored in yellow. Residues that directly contact the DNA (R33, R35, Y36 and C38) are highlighted and marked. NleC cut p65 between residues C38 and E39.



**Fig. S17. Over expression of either NleC or NleBE by the infecting EPEC is sufficient to achieve full inhibition of IL-8 secretion.**

HeLa cells were infected with  $\Delta$ IE2 mutant EPEC, which was used here as wild type, or with a triple mutant  $\Delta$ nleBE,  $\Delta$ nleC ( $\Delta$ nleBEC), or with the triple mutant complemented with plasmids expressing NleC, NleBE or vector (*pnleC*, *pnleBE*, and Vector, respectively). Uninfected and untreated cells served as the positive control (no IL-8 secretion –full repression) and uninfected cells stimulated with TNF $\alpha$  as the negative control (high IL-8 secretion-no repression), respectively. HeLa cells were infected with the relevant EPEC for 3 h to allow injection of effectors before stimulation with TNF $\alpha$  for 16 h. Finally, the growth media was harvested and the amount of secreted IL-8 determined using the ELISA assay.

## References

- Chen, Y.Q., Ghosh, S. and Ghosh, G. (1998) A novel DNA recognition mode by the NF-kappa B p65 homodimer. *Nat Struct Biol*, **5**, 67-73.
- Kallunki, T., Su, B., Tsigelny, I., Sluss, H.K., Derijard, B., Moore, G., Davis, R. and Karin, M. (1994) JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. *Genes Dev*, **8**, 2996-3007.
- Mills, E., Baruch, K., Charpentier, X., Kobi, S. and Rosenshine, I. (2008) Real-time analysis of effector translocation by the type III secretion system of enteropathogenic *Escherichia coli*. *Cell Host Microbe*, **3**, 104-113.
- Nadler, C., Baruch, K., Kobi, S., Mills, E., Haviv, G., Farago, M., Alkalay, I., Bartfeld, S., Meyer, T.F., Ben-Neriah, Y. and Rosenshine, I. (2010) The type III secretion effector NleE inhibits NF-kappaB activation. *PLoS Pathog*, **6**, e1000743.
- Nadler, C., Shifrin, Y., Nov, S., Kobi, S. and Rosenshine, I. (2006) Characterization of enteropathogenic *Escherichia coli* mutants that fail to disrupt host cell spreading and attachment to substratum. *Infect Immun*, **74**, 839-849.
- Schlosser-Silverman, E., Elgrably-Weiss, M., Rosenshine, I., Kohen, R. and Altuvia, S. (2000) Characterization of *Escherichia coli* DNA lesions generated within J774 macrophages. *J Bacteriol*, **182**, 5225-5230.
- Studier, F.W. (2005) Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif*, **41**, 207-234.
- Wiles, S., Clare, S., Harker, J., Huett, A., Young, D., Dougan, G. and Frankel, G. (2004) Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen *Citrobacter rodentium*. *Cell Microbiol*, **6**, 963-972.
- Yaron, A., Hatzubai, A., Davis, M., Lavon, I., Amit, S., Manning, A.M., Andersen, J.S., Mann, M., Mercurio, F. and Ben-Neriah, Y. (1998) Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. *Nature*, **396**, 590-594.